my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Company Portrait
SIRS-Lab produces molecular diagnostic systems to identify life-threatening infections. The main objective is to enable early and targeted antibiotic therapy of sepsis, the leading cause of death in hospitals. With expert knowledge in critical care medicine, microbiology, assay design, and gene expression, SIRS-Lab builds a unique diagnostic portfolio.
SIRS-Lab's new development is the pathogen identification test VYOO. The PCR based test detects 40 bacterial and fungal species that cause life-threatening infections. Simultaneously, 4 important antibiotic resistances are identified. The results are provided within 8 hours.
The core innovation behind VYOO is LOOXSTER, an innovative kit system for sample preparation. LOOXSTER specifically concentrates bacterial and fungal DNA from complex samples optimizing the ratio pro pathogen DNA. Thus, the sensitivity of the subsequent pathogen amplification step is significantly enhanced.
Industrial Sectors
Contact / Request information
Contact the company and request further information free of charge:
Watchlist
This is where you can add this company to your personal favourites
Diagnostics Company SIRS-Lab insolvent
SIRS-Lab requested the opening of insolvency proceedings. The company, founded ten years ago, develops molecular diagnostic technologies for life-threatening infections as sepsis, also known as blood poisoning. Sepsis claims 250.000 victims per year in the USA alone. Therefore SIRS-Lab has ... more
SIRS-Lab announced the inclusion of the first patient in a 1000-patient clinical study evaluating their molecular pathogen test VYOO. The multicenter trial, performed in 11 key centers across Germany and initiated in February 2011, will deliver data about the utility of the PCR test compare ... more
SIRS-Lab and Pfizer to Collaborate in the Field of Sepsis
SIRS-Lab GmbH and Pfizer Pharma GmbH have announced a collaboration in the field of sepsis. The aim of this collaboration is to improve the outcome of patients with life-threatening infection, by using molecular diagnostic tests to achieve the earliest and most accurate targeting of anti-in ... more
Pathogen detection with VYOO(TM)
Sepsis is the most common cause of death in hospitalized patients worldwide. Inadequate antibiotic therapy represents an independent determinant of patients' mortality. Promptness of pathogen detection and the appliance of appropriate antibiotics are the cornerstones of management of severe ... more
Molecular diagnostic test applied to ascitic fluid
Spontaneous bacterial peritonitis (SBP) is a common and life-threatening complication of patients with ascites and cirrhosis of the liver. The mortality accounts for up to 30-50% and such patients die within several hours after infection. An early diagnosis and subsequent antibiotic therapy ... more
LOOXSTER® concentrates bacterial DNA
Detection of the bacterial content of a specific sample, irrelevant from its source, is not as straightforward as it seems. In clinical microbiology laboratories, the gold standard method for the detection of pathogens in patients suspected of systemic infections is the blood culture. Howev ... more
SIRS-Lab produces molecular diagnostic systems to identify life-threatening infections. The main objective is to enable early and targeted antibiotic therapy of sepsis, the leading cause of death in hospitals. With expert knowledge in critical care medicine, microbiology, assay design, and ... more
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
